Sees Translarna CHMP Type II Variation Opinion in Q3, sees FDA Type C meeting for Translarna in 2H. The company also sees Vatiquinone FA FDA Type C meeting in 2H and Sepiapterin NDA submission in Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PTCT:
- PTC Therapeutics to host conference call
- PTC Therapeutics names Pierre Gravier as CFO
- Investors had ‘modest expectations’ for PTC’s vatiquinone, says Morgan Stanley
- Cantor trims PTC Therapeutics target to $73, says vatiquinone not core to story
- PTC study failure has minimal impact on thesis, says William Blair